For the first time, scientists have performed prenatal gene editing using both CRISPR-Cas9 and base editor 3 (BE3) to prevent a lethal metabolic disorder in mice, offering the potential to treat human congenital diseases before birth, as reported today in Nature Medicine.

See the source article by following the link below:
For the first time, scientists have performed prenatal gene editing using both CRISPR-Cas9 and base editor 3 (BE3) to prevent a lethal metabolic disorder in mice, offering the potential to treat human congenital diseases before birth, as reported today in Nature Medicine.